
BerGenBio ASA - Merged with Oncoinvent ASA
About
On 29 October 2025, BerGenBio ASA completed its merger with Oncoinvent ASA. The combined company now operates under the name Oncoinvent ASA. Oncoinvent ASA is alone in developing cancer treatment using alpha radiation for patients with cancer in the abdominal cavity – a condition with very few treatment options and a high rate of recurrence. Preliminary studies show positive research findings. The company has begun recruitment for phase 2 studies, both in Norway and internationally. For more information about the new company, please visit Oncoinvent ASA: https://www.linkedin.com/company/oncoinvent-as/ BerGenBio’s LinkedIn page will be maintained as a historical archive. BerGenBio was a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers.
NO
Jonas Lies vei 91, Bergen, Norway
Public Company
6
Biotechnology Research
Drug discovery; Drug target discovery; Aggressive, drug-resistant cancer; AXL; oncology; acute myeloid leukaemia; Non-small cell lung cancer
Top Decision Makers · 1
Director of Biomarkers and Research
David Micklem
******@***.com
Phone
(**) *** ****
Find the Right Leads
Find Verified Contact Data
What LeadContact does well
Find verified emails, phone numbers, and decision-makers with 98% accuracy.
Find Leads
Find the right people by company, role, industry, location, and more.
925M+ professional profiles

Find Emails
Access verified email addresses for your target contacts.
657M+ emails

Find Phone Numbers
Get cross-validated phone data from multiple top sources.
239M+ phone numbers

More Accurate. Lower Cost.
Find contact data in 1 tool with 98% accuracy
LeadContact integrates leading enrichment tools to deliver more accurate contact data—without paying for each one.
Great conversations start with the right contact.
It’s time to find yours.

